2,3,9,10-TetrahydroxyberberineCAS# 162854-37-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 162854-37-7 | SDF | Download SDF |
PubChem ID | 443768 | Appearance | Powder |
Formula | C17H14NO4 | M.Wt | 296.3 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-2,3,9,10-tetrol | ||
SMILES | C1C[N+]2=C(C=C3C=CC(=C(C3=C2)O)O)C4=CC(=C(C=C41)O)O | ||
Standard InChIKey | DAHMYCXNJSCLGA-UHFFFAOYSA-O | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 2,3,9,10-Tetrahydroxyberberine chloride shows antioxidant activity. |
In vitro | Antioxidant Effect of Berberine and its Phenolic Derivatives Against Human Fibrosarcoma Cells.[Reference: WebLink]Asian Pacific journal of cancer prevention: APJCP, 2015, 16(13):5371-5376.
|
2,3,9,10-Tetrahydroxyberberine Dilution Calculator
2,3,9,10-Tetrahydroxyberberine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.375 mL | 16.8748 mL | 33.7496 mL | 67.4992 mL | 84.3739 mL |
5 mM | 0.675 mL | 3.375 mL | 6.7499 mL | 13.4998 mL | 16.8748 mL |
10 mM | 0.3375 mL | 1.6875 mL | 3.375 mL | 6.7499 mL | 8.4374 mL |
50 mM | 0.0675 mL | 0.3375 mL | 0.675 mL | 1.35 mL | 1.6875 mL |
100 mM | 0.0337 mL | 0.1687 mL | 0.3375 mL | 0.675 mL | 0.8437 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- IEM 1754 dihydrobroMide
Catalog No.:BCC5049
CAS No.:162831-31-4
- 7-Epi-10-oxo-docetaxel
Catalog No.:BCC5410
CAS No.:162784-72-7
- LJI308
Catalog No.:BCC6538
CAS No.:1627709-94-7
- PFI-2
Catalog No.:BCC5561
CAS No.:1627676-59-8
- Yunnancoronarin A
Catalog No.:BCN1723
CAS No.:162762-93-8
- WAY-100635
Catalog No.:BCC2053
CAS No.:162760-96-5
- Anemarrhena B
Catalog No.:BCN7592
CAS No.:1627521-95-2
- LDN-214117
Catalog No.:BCC5528
CAS No.:1627503-67-6
- AZD8186
Catalog No.:BCC6470
CAS No.:1627494-13-6
- 1-Hydroxy-2-prenylnaphthalene
Catalog No.:BCN1722
CAS No.:16274-34-3
- 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran
Catalog No.:BCN1539
CAS No.:16274-33-2
- Kaempferol tetraacetate
Catalog No.:BCN1721
CAS No.:16274-11-6
- Polygalasaponin V
Catalog No.:BCN2790
CAS No.:162857-65-0
- Polygalaxanthone III
Catalog No.:BCN2354
CAS No.:162857-78-5
- Antibiotic AB 4015B
Catalog No.:BCN1826
CAS No.:162857-79-6
- (S)-3,5-DHPG
Catalog No.:BCC6802
CAS No.:162870-29-3
- Kaempferol-7-O-D-glucopyranoside
Catalog No.:BCN2296
CAS No.:16290-07-6
- 3,4-Dihydroxybenzylamine Hydrobromide
Catalog No.:BCC8280
CAS No.:16290-26-9
- Bis(4-bromophenyl)amine
Catalog No.:BCC8883
CAS No.:16292-17-4
- K-Ras G12C-IN-1
Catalog No.:BCC5538
CAS No.:1629265-17-3
- K-Ras G12C-IN-2
Catalog No.:BCC5539
CAS No.:1629267-75-9
- K-Ras G12C-IN-3
Catalog No.:BCC5540
CAS No.:1629268-19-4
- 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3
Catalog No.:BCC1309
CAS No.:163018-26-6
- 2-Cl-IB-MECA
Catalog No.:BCC6938
CAS No.:163042-96-4
Oxygen Vacancy Promoted Heterogeneous Fenton-like Degradation of Ofloxacin at pH 3.2-9.0 by Cu Substituted Magnetic Fe3O4@FeOOH Nanocomposite.[Pubmed:28934546]
Environ Sci Technol. 2017 Nov 7;51(21):12699-12706.
To develop an ultraefficient and reusable heterogeneous Fenton-like catalyst at a wide working pH range is a great challenge for its application in practical water treatment. We report an oxygen vacancy promoted heterogeneous Fenton-like reaction mechanism and an unprecedented ofloxacin (OFX) degradation efficiency of Cu doped Fe3O4@FeOOH magnetic nanocomposite. Without the aid of external energy, OFX was always completely removed within 30 min at pH 3.2-9.0. Compared with Fe3O4@FeOOH, the pseudo-first-order reaction constant was enhanced by 10 times due to Cu substitution (9.04/h vs 0.94/h). Based on the X-ray photoelectron spectroscopy (XPS), Raman analysis, and the investigation of H2O2 decomposition, (*)OH generation, pH effect on OFX removal and H2O2 utilization efficiency, the new formed oxygen vacancy from in situ Fe substitution by Cu rather than promoted Fe(3+)/Fe(2+) cycle was responsible for the ultraefficiency of Cu doped Fe3O4@FeOOH at neutral and even alkaline pHs. Moreover, the catalyst had an excellent long-term stability and could be easily recovered by magnetic separation, which would not cause secondary pollution to treated water.
Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells.[Pubmed:28887921]
Phytomedicine. 2017 Sep 15;33:62-68.
INTRODUCTION: Malignacies are still a major public concern worldwide and despite the intensive search of new chemotherapeutic agents, treatment still remains a challenging issue. The present study was designed to evaluate the cytotoxicity of 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone (AMNQ) isolated from the bark of Milletia versicolor towards a panel of drug-sensitive and multidrug-resistant (MDR) cancer cell lines. METHODS: The resazurin reduction assay was used to evaluate the cytotoxicity of AMNQ against 9 drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Cell cycle, mitochondrial membrane potential (MMP) and levels of reactive oxygen species were all analyzed by flow cytometry. RESULTS: Following resazurin assay, the naphthoquinone AMNQ displayed IC50 values ranging from 0.79microM (against HepG2 hepatocarcinoma cells) to 3.26microM (against MDA-MB231/BCRP breast cancer cells) on 9 tested cancer cell lines, whilst doxorubicin showed IC50 values ranging from 0.40microM (against CCRF-CEM leukemia cells) to 91.37microM (against CEM/ADR5000 leukemia cells). IC50 values below 1microM were recorded with AMNQ towards CCRF-CEM cells (0.57microM), U87MG.DeltaEGFR gliobastoma multiforme cells (0.96microM cells) and HepG2 cells (0.76microM). Compared to its corresponding sensitive cell lines U87MG, sensitivity was observed in epidermal growth factor receptor-transfected U87MG.DeltaEGFR cells to AMNQ. MMP was found to be the main mode of action of induction of apoptosis by AMNQ. CONCLUSIONS: The results of this work demonstrate the cytotoxicity of AMNQ towards various types of cancer cell lines, including MDR phenotypes. AMNQ is a potential antiproliferative natural compound that deserves more investigations to develop novel cytotoxic drugs against sensitive and MDR cancers.
Crystal structure and DFT study of (E)-N-[2-(1H-indol-3-yl)eth-yl]-1-(anthracen-9-yl)methanimine.[Pubmed:28932467]
Acta Crystallogr E Crystallogr Commun. 2017 Aug 11;73(Pt 9):1329-1332.
The title compound, C25H20N2, (I), was synthesized from the condensation reaction of anthracene-9-carbaldehyde and tryptamine in dry ethanol. The indole ring system (r.m.s. deviation = 0.016 A) makes a dihedral angle of 63.56 (8) degrees with the anthracene ring (r.m.s. deviation = 0.023 A). There is a short intra-molecular C-Hcdots, three dots, centeredN inter-action present, and a C-Hcdots, three dots, centeredpi inter-action involving the two ring systems. In the crystal, the indole H atom forms an inter-molecular N-Hcdots, three dots, centeredpi inter-action, linking mol-ecules to form chains along the b-axis direction. There are also C-Hcdots, three dots, centeredpi inter-actions present, involving the central and terminal rings of the anthracene unit, linking the chains to form an overall two-dimensional layered structure, with the layers parallel to the bc plane. The density functional theory (DFT) optimized structure, at the B3LYP/6-311 G(d,p) level, is compared with the experimentally determined mol-ecular structure in the solid state.
After 9 Years of 3-Column Osteotomies, Are We Doing Better? Performance Curve Analysis of 573 Surgeries With 2-Year Follow-up.[Pubmed:28973410]
Neurosurgery. 2018 Jul 1;83(1):69-75.
BACKGROUND: In spinal deformity treatment, the increased utilization of 3-column (3CO) osteotomies reflects greater comfort and better training among surgeons. This study aims to evaluate the longitudinal performance and adverse events (complications or revisions) for a multicenter group following a decade of 3CO. OBJECTIVE: To investigate if performance of 3CO surgeries improves with years of practice. METHODS: Patients who underwent 3CO for spinal deformity with intra/postoperative and revision data collected up to 2 yr were included. Patients were chronologically divided into 4 even groups. Demographics, baseline deformity/correction, and surgical metrics were compared using Student t-test. Postoperative and revision rates were compared using Chi-square analysis. RESULTS: Five hundred seventy-three patients were stratified into: G1 (n = 143, 2004-2008), G2 (n = 142, 2008-2009), G3 (n = 144, 2009-2010), G4 (n = 144 2010-2013). The most recent patients were more disabled by Oswestry disability index (G4 = 49.2 vs G1 = 38.3, P = .001), and received a larger osteotomy resection (G4 = 26 degrees vs G1 = 20 degrees , P = .011) than the earliest group. There was a decrease in revision rate (45%, 35%, 33%, 30%, P = .039), notably in revisions for pseudarthrosis (16.7% G1 vs 6.9% G4, P = .007). Major complication rates also decreased (57%, 50%, 46%, 39%, P = .023) as did excessive blood loss (>4 L, 27.2 vs 16.7%, P = .023) and bladder/bowel deficit (4.2% vs 0.7% P = .002). Successful outcomes (no complications or revision) significantly increased (P = .001). CONCLUSION: Over 9 yr, 3COs are being performed on an increasingly disabled population while gaining a greater correction at the osteotomy site. Revisions and complication rate decreased while success rate improved during the 2-yr follow-up period.